All articles by Srivani Venna

Srivani Venna

GlycoMimetics reports positive data from Phase Ia trial of GMI-1687

The trial met the primary and secondary endpoints of safety, tolerability and pharmacokinetics.

PharmAbcine publishes preclinical data on PMC-403 for ISCLS

The antibody received FDA orphan drug designation to treat systemic capillary leak syndrome earlier this year.

Walgreens partners with CRF for PREVUE-VALVE clinical trial

Under the partnership, Walgreens will provide patient recruitment services to support the ongoing trial.

IMUNON treats first patient in ovarian cancer therapy trial

The detection of minimal residual disease by second-look laparoscopy is the primary endpoint of the study.

SynAct’s study of rheumatoid arthritis therapy fails to meet endpoint

An improved ACR20 response was observed in 54.7% of patients treated with resomelagon, against 55.7% of patients receiving a placebo.

NextPoint doses first subject with NPX267 to treat solid tumours

NPX267 targets killer cell immunoglobulin-like receptor 3DL3 and helps prevent immune escape in solid tumours.

University of the Sunshine Coast to begin trial of Covid-19 medication

Eligible participants for the trial need to attend up to 12 visits at the Sunshine Coast clinic for around 15 months.

Lindus Health raises funding to scale up clinical trials

Lindus Health plans to launch clinical trials for menopause, insomnia, tinnitus, and childhood myopia treatments.

Verily and OneOncology establish partnership for clinical trials

SignalPath will configure study protocol workflows within the platform and save time and effort of the site staff.

Disc reports positive results from Phase II trial of EPP therapy

Bitopertin was well-tolerated at both dose levels and no serious adverse events were reported.